Health Care [ 12/12 ] | Biotechnology [ 64/73 ]
NASDAQ | Common Stock
Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China.
It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
The company offers next-generation sequencing (NGS) based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various cancer types, including pan-cancer, lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, and ovarian cancer.
Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples, and OncoCompass, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore, which assesses microsatellite loci related to MSI status and detects mutations in genes associated with gastrointestinal cancers.
It also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of the key products.
The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA.
Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 3, 25 | -0.17 Increased by +89.55% | - |
| Mar 26, 25 | -1.09 Increased by +64.38% | - |
| Dec 18, 24 | -0.48 Increased by +71.75% | - |
| Aug 29, 24 | -1.45 Decreased by -13.59% | - |
| May 29, 24 | -1.65 Increased by +8.90% | -1.10 Decreased by -49.91% |
| Mar 28, 24 | -3.07 Decreased by -830.30% | -3.24 Increased by +5.25% |
| Nov 30, 23 | -1.71 Increased by +23.32% | -1.32 Decreased by -29.55% |
| Aug 31, 23 | -1.28 Increased by +48.80% | -1.86 Increased by +31.18% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 133.08 M Increased by +5.94% | -13.50 M Increased by +88.89% | Decreased by -10.14% Increased by +89.52% |
| Dec 31, 24 | 126.02 M Increased by +4.08% | -81.29 M Increased by +49.88% | Decreased by -64.51% Increased by +51.85% |
| Sep 30, 24 | 128.64 M Increased by +0.85% | -35.74 M Increased by +79.57% | Decreased by -27.79% Increased by +79.74% |
| Jun 30, 24 | 135.53 M Decreased by -7.34% | -108.04 M Increased by +17.68% | Decreased by -79.71% Increased by +11.16% |
| Mar 31, 24 | 125.62 M Decreased by -11.85% | -121.55 M Increased by +34.39% | Decreased by -96.76% Increased by +25.56% |
| Dec 31, 23 | 121.08 M Decreased by -14.87% | -162.21 M Increased by +24.98% | Decreased by -133.97% Increased by +11.87% |
| Sep 30, 23 | 127.57 M Decreased by -17.50% | -174.98 M Increased by +22.68% | Decreased by -137.17% Increased by +6.28% |
| Jun 30, 23 | 146.27 M Increased by +11.79% | -131.24 M Increased by +49.93% | Decreased by -89.73% Increased by +55.21% |